Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Financing Activities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash from Financing Activities for 10 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 121.72% to -$4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2025, up 46.84% year-over-year, with the annual reading at $72.9 million for FY2025, 46.84% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$4.8 million at Akebia Therapeutics, down from $1.1 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $74.9 million in Q1 2025, with the low at -$32.9 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $12.3 million, with a median of $1.5 million recorded in 2024.
  • The sharpest move saw Cash from Financing Activities tumbled 128900.0% in 2023, then skyrocketed 2346.0% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $5.4 million in 2021, then crashed by 100.02% to -$1000.0 in 2022, then crashed by 128900.0% to -$1.3 million in 2023, then skyrocketed by 1830.62% to $22.3 million in 2024, then plummeted by 121.72% to -$4.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$4.8 million, $1.1 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.